Workflow
济川药业(600566) - 2017 Q1 - 季度财报
JUMPCANJUMPCAN(SH:600566)2017-04-28 16:00

Financial Performance - Net profit attributable to shareholders rose by 39.01% to CNY 290,711,134.09 year-on-year[7] - Operating revenue grew by 21.46% to CNY 1,404,813,083.30 compared to the same period last year[7] - The weighted average return on equity increased by 0.1 percentage points to 7.64%[7] - The company reported an operating profit of CNY 300,473,676.33, which is a 34.2% increase from CNY 223,898,488.90 in Q1 2016[30] - Net profit for Q1 2017 was CNY 291,195,912.74, representing a growth of 39.4% from CNY 208,742,032.18 in Q1 2016[30] - Earnings per share for Q1 2017 was CNY 0.359, up from CNY 0.268 in the previous year, indicating a 33.9% increase[31] - The total comprehensive income for Q1 2017 was a loss of CNY 883,448.89, slightly better than the loss of CNY 911,385.51 in Q1 2016, reflecting a minor improvement in overall financial performance[34] Assets and Liabilities - Total assets increased by 6.93% to CNY 5,333,044,646.47 compared to the end of the previous year[7] - The company's total assets increased to 5,333,044,646.47 RMB, up from 4,987,611,648.59 RMB at the beginning of the year[22] - Total liabilities increased to CNY 1,434,340,604.11 from CNY 1,300,103,518.97, marking an increase of 10.3%[24] - The company's total equity rose to CNY 3,898,704,042.36, up from CNY 3,657,337,648.36, which is an increase of 6.6%[24] - The company's non-current liabilities totaled 54,178,313.20 RMB, with a slight decrease from the previous period[23] Cash Flow - The net cash flow from operating activities increased by 20.72% to CNY 339,012,265.69 year-on-year[7] - Operating cash flow for Q1 2017 was CNY 339,012,265.69, an increase from CNY 280,833,860.20 in Q1 2016, reflecting a growth of approximately 20.5%[35] - The company reported cash inflows from operating activities totaling CNY 1,540,409,980.12, compared to CNY 1,270,643,368.16 in the previous year, showing an increase of approximately 21.2%[35] - The company reported a net cash increase for Q1 2017 of CNY 177,522,900.41, compared to CNY 199,535,660.54 in Q1 2016, showing a decrease of approximately 11.0%[36] Investments - The company reported a net cash flow from investment activities of -161,367,744.55 RMB, a decrease of 98.57% compared to the previous period[14] - Investment activities resulted in a net cash outflow of CNY 161,367,744.55 in Q1 2017, compared to a net outflow of CNY 81,266,765.62 in Q1 2016, indicating a significant increase in investment expenditures[36] - The company completed the acquisition of the remaining 20% equity in Shaanxi Dongke Pharmaceutical, making it a wholly-owned subsidiary[14] Shareholder Information - The number of shareholders reached 8,808 at the end of the reporting period[11] Other Financial Metrics - Prepayments increased by 119.09% to CNY 34,395,635.61 due to increased raw material prepayments and equity acquisition prepayments[13] - Other receivables rose by 52.83% to CNY 13,268,593.09 mainly due to increased travel loans and petty cash[13] - Tax payable increased by 33.81% to CNY 123,846,623.89 due to the expansion of sales scale[13] - Other payables increased by 37.94% to CNY 697,931,693.72 primarily due to increased market personnel expenses[13] - Financial expenses decreased by 154.29%, resulting in -2,590,603.05 RMB, attributed to increased interest income[14] - The company plans to adjust its convertible bond issuance strategy after withdrawing the previous application, aiming to raise up to 975 million RMB for various projects[16] - The company’s inventory slightly decreased to 202,271,989.17 RMB from 204,401,819.04 RMB, indicating a minor reduction of 1.1%[22] - The company reported a 37.77% increase in taxes and surcharges, totaling 28,653,752.52 RMB, primarily due to a change in accounting policy[14] - Operating costs for Q1 2017 were CNY 1,106,115,794.77, a rise of 18.6% from CNY 932,721,463.10 in the previous year[30] - The total liabilities to equity ratio as of March 31, 2017, was approximately 36.8%, reflecting the company's leverage position[24] - The company’s management expenses decreased to CNY 882,216.98 from CNY 910,570.72, reflecting a reduction of about 3.1%[34]